Morganti, S., Jin, Q., Vincuilla, J., Buehler, R., Ryan, S., Stokes, S., . . . Lynce, F. (2024). Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ Breast Cancer. https://doi.org/10.1038/s41523-024-00632-8
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Morganti, Stefania, et al. "Clinicopathological Characteristics and Eligibility for Adjuvant Olaparib of Germline BRCA1/2 Mutation Carriers with HER2-negative Early Breast Cancer."
NPJ Breast Cancer 2024. https://doi.org/10.1038/s41523-024-00632-8.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Morganti, Stefania, et al. "Clinicopathological Characteristics and Eligibility for Adjuvant Olaparib of Germline BRCA1/2 Mutation Carriers with HER2-negative Early Breast Cancer."
NPJ Breast Cancer, 2024, https://doi.org/10.1038/s41523-024-00632-8.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.